Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02050919 · ClinicalTrials.gov registry record · Phase 2
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
A Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02050919: Completed Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7, sponsored by OHSU Knight Cancer Institute.
NCT02050919 is a Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7 that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02050919, a Phase 2 study of Pleomorphic Rhabdomyosarcoma and Stage III Adult Soft Tissue Sarcoma AJCC v7, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin hydrochloride and ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells. Giving sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery may be an effective treatment for soft tissue sarcoma.
Primary Outcome
Descriptive statistical analysis will be conducted. The proportion with 95% confidence interval will be summarized.
Conditions Studied
Interventions
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- DRUG Ifosfamide
- DRUG Sorafenib Tosylate
- DRUG Epirubicin Hydrochloride
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-12-03 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 2 |
What the finished NCT02050919 record still lists
NCT02050919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Pleomorphic Rhabdomyosarcoma appearing as the primary indexed condition, and to 5 interventions - of which External Beam Radiation Therapy is the first listed.
NCT02050919 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02050919 about?
NCT02050919 is a clinical study titled "Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma". This phase II trial studies how well sorafenib tosylate, combination chemotherapy, radiation therapy, and surgery work in treating patients with high-risk stage IIB-IV soft tissue sarcoma. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. D...
What is the current status of trial NCT02050919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-12-03. Estimated completion is 2020-12-31.
What conditions does trial NCT02050919 study?
This clinical trial studies the following conditions: Pleomorphic Rhabdomyosarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7.
What interventions are being tested in trial NCT02050919?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Ifosfamide (DRUG), Sorafenib Tosylate (DRUG), Epirubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02050919?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02050919 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pleomorphic Rhabdomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02050919's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI